Nexalis Therapeutics Limited
Research Nexalis Therapeutics Limited (NX1.AX) on Bullrun: market cap AUD 2.28M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNX1.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 2.28M
- Financial periodFY2025
- Net income-AUD 1.62M
- Free cash flow-AUD 888.17K
Valuation Snapshot
latest market cap is AUD 2.28M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 1.62M | -AUD 888.17K | n/a | -0.01 | AUD 436.90K | AUD 741.28K | -AUD 1.18M |
| FY2024 | n/a | -AUD 1.21M | -AUD 368.77K | n/a | -0.01 | AUD 194.92K | AUD 34.06K | -AUD 63.97K |
| FY2023 | n/a | -AUD 1.44M | -AUD 1.96M | n/a | -0.01 | AUD 715.82K | AUD 560.28K | AUD 665.47K |
| FY2022 | AUD 24.80K | -AUD 1.90M | -AUD 1.85M | 100.0% | -0.01 | AUD 2.13M | n/a | AUD 1.93M |
| FY2021 | AUD 167.30K | n/a | n/a | 31.1% | n/a | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 2.28M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Nexalis Therapeutics Limited
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nexalis Therapeutics Limited's market cap?
Nexalis Therapeutics Limited's market capitalization is AUD 2.28M.
What does Nexalis Therapeutics Limited do?
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026.